Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status

Fatna Laidi,1 Amal Bouziane,2 Amina Lakhdar,3 Samira Khabouze,3 Brahim Rhrab,3 Fatima Zaoui1 1Oral Biomechanics and Biotechnology Research Unit, Faculty of Dental Medicine, 2Department of Periodontology, Faculty of Dental Medicine, Biostatistical, Clinical and Epidemiological Research Laboratory, F...

Full description

Bibliographic Details
Main Authors:	Laidi F, Bouziane A, Lakhdar A, Khabouze S, Rhrab B, Zaoui F
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-07-01
Series:	OncoTargets and Therapy
Online Access:	http://www.dovepress.com/salivary-expression-of-soluble-her2-in-breast-cancer-patients-with-pos-a17583

Similar Items

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
by: I. P. Ganshina, et al.
Published: (2019-06-01)

Salivary Protein Profiles among HER2/neu-Receptor-Positive and -Negative Breast Cancer Patients: Support for Using Salivary Protein Profiles for Modeling Breast Cancer Progression
by: Charles F. Streckfus, et al.
Published: (2012-01-01)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
by: Yu Ishimine, et al.
Published: (2015-01-01)

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
by: Qin T, et al.
Published: (2013-04-01)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
by: Mari Hosonaga, et al.
Published: (2018-07-01)

Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer
by: Sylwia Dębska-Szmich, et al.
Published: (2015-05-01)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: Anna Burguin, et al.
Published: (2020-01-01)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
by: Nindo B. Punturi, et al.
Published: (2021-05-01)

STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE
by: A. N. Stukov, et al.
Published: (2019-11-01)

Bevacizumab in the treatment of HER2-negative breast cancer
by: Vito Lorusso
Published: (2008-11-01)

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
by: Sae-Won Han, et al.
Published: (2012-01-01)

Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis
by: Zhou C, et al.
Published: (2018-09-01)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
by: James Crespo, et al.
Published: (2020-01-01)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: PLOS ONE Staff
Published: (2020-01-01)

Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.
by: Praveenkumar K Shetty, et al.
Published: (2012-01-01)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor
by: Nick Beije, et al.
Published: (2016-11-01)

HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features
by: Lin He, et al.
Published: (2021-04-01)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
by: Antonio Fernando Leis-Filho, et al.
Published: (2021-06-01)

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
by: Jie Li, et al.
Published: (2020-09-01)

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
by: Yi Ding, et al.
Published: (2018-10-01)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
by: Fara Brasó-Maristany, et al.
Published: (2020-01-01)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
by: Maria Gaibar, et al.
Published: (2020-01-01)

Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients
by: Alaa Mohamed Maria, et al.
Published: (2018-06-01)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
by: Avisek Majumder, et al.
Published: (2021-04-01)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
by: Maria Vittoria Dieci, et al.
Published: (2019-11-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

Change in HER-2/neu Status from Negative to Positive following Treatment in Breast Cancer: A Case Report
by: Lakshmi Sivarajan, et al.
Published: (2011-01-01)

Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients
by: Henry L. Gómez, et al.
Published: (2010-07-01)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
by: Laura Pizzuti, et al.
Published: (2021-07-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Neoadjuvant therapy for HER2-positive breast cancer
by: Nikolina Dukić, et al.
Published: (2019-06-01)

Interlaboratory concordance in HER-2 positive breast cancer
by: Nives Jonjić, et al.
Published: (2015-01-01)

Treatment of HER2 positive breast cancer patients
by: Erika Matos
Published: (2012-03-01)

Educational Case: HER-2 Positive Breast Cancer
by: Julia Jennings MD, et al.
Published: (2021-09-01)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
by: Praveenkumar K. Shetty, et al.
Published: (2012-01-01)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer.
by: Praveenkumar K. Shetty, et al.
Published: (2012-01-01)

Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)

POSSIBILITIES OF THERAPY OF HER-2-POSITIVE REGIONAL BREAST CANCER
by: A. S. Belokhvostova, et al.
Published: (2015-04-01)

Cannot write session to /tmp/vufind_sessions/sess_t51mbp8o6691a6lcu5od5s327n